T&R Biofab Co. Ltd (246710) - Total Assets
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) holds total assets worth ₩83.86 Billion KRW (≈ $56.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
T&R Biofab Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's total assets have evolved over time, based on quarterly financial data. Also see T&R Biofab Co. Ltd (246710) total market value for the company's overall valuation and market capitalisation.
T&R Biofab Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
T&R Biofab Co. Ltd's total assets of ₩83.86 Billion consist of 26.7% current assets and 73.3% non-current assets. Review T&R Biofab Co. Ltd (246710) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.67 Billion | 16.9% |
| Accounts Receivable | ₩2.20 Billion | 2.2% |
| Inventory | ₩4.72 Billion | 4.8% |
| Property, Plant & Equipment | ₩61.33 Billion | 62.3% |
| Intangible Assets | ₩1.33 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See T&R Biofab Co. Ltd (246710) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: T&R Biofab Co. Ltd's current assets represent 26.7% of total assets in 2024, a decrease from 55.9% in 2015.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 53.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.3% of total assets.
T&R Biofab Co. Ltd Competitors by Total Assets
Key competitors of T&R Biofab Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €408.98 Million |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
DRTECH Corporation
KQ:214680
|
Korea | ₩235.84 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €62.52 Million |
T&R Biofab Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.42 | 0.85 | 35.42 |
| Quick Ratio | 0.32 | 0.76 | 32.46 |
| Cash Ratio | 0.00 | 0.39 | 0.00 |
| Working Capital | ₩-22.87 Billion | ₩-6.02 Billion | ₩41.62 Billion |
T&R Biofab Co. Ltd - Advanced Valuation Insights
This section examines the relationship between T&R Biofab Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | ₩98.45 Billion |
| Market Capitalization | $47.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values T&R Biofab Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: T&R Biofab Co. Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual total assets of T&R Biofab Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩98.45 Billion ≈ $66.72 Million |
-1.37% |
| 2023-12-31 | ₩99.82 Billion ≈ $67.64 Million |
+31.44% |
| 2022-12-31 | ₩75.94 Billion ≈ $51.46 Million |
-7.66% |
| 2021-12-31 | ₩82.23 Billion ≈ $55.73 Million |
+69.54% |
| 2020-12-31 | ₩48.51 Billion ≈ $32.87 Million |
+79.07% |
| 2019-12-31 | ₩27.09 Billion ≈ $18.36 Million |
-12.91% |
| 2018-12-31 | ₩31.10 Billion ≈ $21.08 Million |
+228.56% |
| 2017-12-31 | ₩9.47 Billion ≈ $6.42 Million |
-1.27% |
| 2016-12-31 | ₩9.59 Billion ≈ $6.50 Million |
+75.95% |
| 2015-12-31 | ₩5.45 Billion ≈ $3.69 Million |
-- |
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.